- Home
- SCSC vs PHAT Comparison
SCSC vs PHAT Comparison
Compare SCSC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCSC | PHAT |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 892.3M | 942.6M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SCSC | PHAT |
|---|---|---|
| Price | $38.92 | $15.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $43.00 | $17.33 |
| AVG Volume (30 Days) | 197.4K | ★ 807.3K |
| Earning Date | 01-29-2026 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.79 | N/A |
| EPS | ★ 3.20 | N/A |
| Revenue | ★ $3,004,880,000.00 | $147,190,000.00 |
| Revenue This Year | $5.40 | $220.37 |
| Revenue Next Year | $5.34 | $83.14 |
| P/E Ratio | $12.22 | ★ N/A |
| Revenue Growth | N/A | ★ 460.30 |
| 52 Week Low | $28.75 | $2.21 |
| 52 Week High | $52.06 | $18.31 |
Technical Indicators
Market Signals| Indicator | SCSC | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 38.59 | 49.05 |
| Support Level | $38.75 | $16.77 |
| Resistance Level | $39.68 | $16.98 |
| Average True Range (ATR) | 1.07 | 0.78 |
| MACD | -0.20 | -0.14 |
| Stochastic Oscillator | 9.24 | 36.86 |
Price Performance
Historical ComparisonAbout SCSC ScanSource Inc.
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Modern Communications and Cloud. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.